Cheaper weight-loss drugs, including Ozempic, may transform India's health market

India may soon see a major shift in obesity and diabetes treatment as the patent for semaglutide, a key ingredient in popular weight-loss drugs including Ozempic, has reportedly expired in the country, as per reports.

This is expected to let Indian pharmaceutical companies launch affordable versions, making these medicines accessible to more people.

According to reports, several leading drugmakers are preparing to introduce generic versions, which could reduce monthly treatment costs with drugs like Ozempic from around ₹10,000 to ₹16,000 to nearly ₹3,000 to ₹5,000. This price drop may significantly increase demand, especially in a country where millions struggle with obesity and type 2 diabetes.

Semaglutide belongs to a class of medicine that helps control blood sugar and reduce appetite, helping patients feel full for longer. Initially developed for diabetes, it has reportedly gained global attention for its effectiveness in weight loss.

Experts believe this could be a turning point for India’s pharmaceutical industry, which is already known for producing low-cost generic medicines. According to reports, the domestic market for such drugs could grow rapidly, with strong export potential as well.​

However, doctors have urged caution. These medicines can cause side effects like nausea and digestive issues, and in rare cases, more serious complications. Reportedly, these are also concerns about misuse, especially with the easier availability and influence of social media trends promoting quick weight loss.

Medical professionals stress that these drugs are not a shortcut. Proper diet, exercise, and medical supervision are still essential. According to experts, long-term use may be required, and stopping the medication could lead to weight regain.

​